LDH is a well-known metastatic melanoma biomarker, and since 2009, it has been included as a recommendation in melanoma staging guidelines; recent reports have shown that elevated baseline values of LDH are correlated with poor survival and response rates in melanoma patients treated with anti-PD-1. Here, PDCD1 is linked to metastatic melanoma.